Advances in diagnosis and treatment on human granulocytic anaplasmosis

Abstract

Abstract: Human granulocytic anaplasmosis (HGA) is an emerging tick-borne natural focal disease caused by Anaplasma phagocytophilum.Its clinical characters mainly include symptoms of febrile illness, digestive tract and blood system.A few severe patients die with multiple system organ failure.The cases of HGA were recently reported in America, Europe and Africa, and also found in our country.The disease has attracted more attention.The advances of diagnosis and treatments on HGA is reviewed in this article.

Key words: Ehrlichia, human granulocytic anaplasmosis, diagnosis, treatment

CLC Number:

R376

YU Yan-lin, YANG Jin-sun, RUI Jing. Advances in diagnosis and treatment on human granulocytic anaplasmosis[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(9): 980-983.

References

1 Dumler JS.Anaplasma and Ehrlichia infenction [J].Ann N Y Acad Sci, 2005;1063:361-373.
2 Strle E.Human granulocytic ehrlichiosis in Europe [J].Int J Med Microbiol, 2004;37:27-35.
3 Dumler JS, Barat NC, Barat CE, et al.Human granulocytic anaplasmosis and macrophage activation [J].Clin Infect Dis, 2007;45:199-204.
4 高东旗, 曹务春, 张习坦, 等.大兴安岭地区人群埃立克体感染的调查 [J].中华流行病学, 2001;22 :137-141.
5 Grzeszczuk A.Anaplasma phagocytophilum in Ixodes ricinus ticks and human granulocytic anaplasmosis seroprevalence among forestry rangers in Bia ? y stok region [J].Adv Med Sci, 2006; 51:283-286.
6 Demma LJ, Holman RC, Mcquiston JH, et al.Epidemiology of human ehrlichiosis and anaplasmosis in the United States, 2001-2002 [J].Am J Trop Med Hyg, 2005;73 :400-409.
7 贺联印, 许炽瞟.热带病学 [M].第2 版.北京:人民卫生出版社, 2004:371-381.
8 Dhand A, Nadelman RB, Aguero-Rosenfeld M, et al.Human granulocytic anaplasmosis during pregnancy :case series and literature review [J].Clin Infect Dis, 2007;45 :589-593.
9 Zhang JZ, Guo H, Winslow GM, et al.Expression of members of the 28-kilodalton major outer membrane protein family of ehrlichia chaffeensis during persistent infection [J].Infect Immun, 2004;72:4336-4343.
10 Choi KS, Dumler JS.A mitogenic component in polar lipid-enriched A.phagocytophilum membranes [J].Clin Vaccine Immunol, 2007;(In Print)
11 Bitsaktsis C, Huntington J, Winslow G.Production of IFNgamma by CD4 T cells is essential for resolving Ehrlichia infection [J].J Immunol, 2004;172 :6894-6901.
12 Choi KS, Webb T, Oelke M, et al.Differential innate immune cell activation and proinflammatory response in Anaplasma phagocytophilum infection [J].Infect Immun, 2007;75 :3124-3130.
13 Dumler JS, Madigan JE, Pusterla N, et al.Ehrlichioses in humans: epidemiology, clinical presentation, diagnosis, and treatment [J].Clin Infect Dis, 2007;45:S45-51.
14 Walker DH.Ehrlichia under our noses and no one notices [J]. Arch Virol, 2005;19:147-156.
15 Chapman AS, Bakken JS, Folk SM, et al.Diagnosis and management of tickborne rickettsial diseases :Rocky Mountain spotted fever, ehrlichioses, and anaplasmosis-United States [J]. MMWR Recomm Rep, 2006;55:1-27.
16 Alberti A, Sparagano OA.Molecular diagnosis of granulocytic anaplasmosis and infectious cyclic thrombocytopenia by PCRRFLP [J].Ann N Y Acad Sci, 2006;1081 :371-378.
17 Martinez D, Vachiery N, Stachruski F, et al.Nested PCR for detection and genotyping of Ehrlichia ruminantium :use in genetic diversity analysis [J].Ann N Y Acad Sci, 2004;1026: 106-113.
18 Blas-Machado U, de la Fuente J, Blouin EF, et al.Experimental infection of C³H HeJ mice with the NY18 isolate of Anaplasma phagocytophilum [J].Vet Pathol, 2007;44:64-73.
19 Gardner SL, Holman RC, Krebs JW, et al.National surveillance for the human ehrlichioses in the United States, 1997-2001, and proposed methods for evaluation of data quality [J]. Ann N Y Acad Sci, 2003;990 :80-89.
20 Brouqui P, Bacellar F, Baranton G, et al.Guidelines for the diagnosis of tick-borne bacterial diseases in Europe [J].Clin Microbiol Infect, 2004;10:1108-1132.
21 Bakken JS, Dumler JS.Clinical diagnosis and treatment of human granulocytotropic anaplasmosis [J].Ann N Y Acad Sci, 2006;1078:236-247.
22 Branger S, Rolain JM, Raoult D.Evaluation of antibiotic susceptibilities of Ehrlichia canis, Ehrlichia chaffeensis and Anaplasma phagocytophilum by real-time PCR [J].Antimicrob Agents Chemother, 2004;48:4822-4828.

[1]	FU Xiaoyu, KONG Deguang, LI Juanjuan. Treatment progress of triple positive breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 866-875.
[2]	WANG Chaoyi, SONG Qiang, XIONG Xin, WANG Mengyuan. Research progress on diagnosis and treatment of granulomatous lobular mastitis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 910-917.
[3]	WANG Juan, LIU Weiying, YE Yucai, FU Wenli, ZHANG Sha, LI Leping. Research progress of norepinephrine reuptake inhibitor combined with antimuscarinic in the treatment of obstructive sleep apnea [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 714-720.
[4]	LI Shuang, HAN Shuzhen, DAI Yuting, XIU Minghui, DU Xianqin, HE Jianzheng, LIN Xingyao. Progress in the prevention and treatment of traditional Chinese medicine based on the mechanism of intestinal injury of various chemotherapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 583-593.
[5]	TAO Yijia, YANG Chun, LIU Cunming . Progress in clinical application of topical anesthesia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 594-600.
[6]	ZHANG Li, LIN Xingyao, SHANG Yun, WANG Qiang. Progress on the pathological mechanism and treatment of frostbite [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 347-354.
[7]	DANG Yangbin, LIANG Yuxin, WANG Tiancheng. Research progress on the related treatment of progressive myoclonic epilepsy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1184-1194.
[8]	JIA Tao, TENG Jinliang. New narcotic analgesics: esketamine [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 834-840.
[9]	DING Hao, GAO Zhenhua, ZHENG Yun. Research progress of microRNA in diagnosis and treatment of prostate cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 696-708.
[10]	SHI Jingbin, XIONG Yang. Research progress on interaction between tumor microenvironment and breast cancer cells leading to tumor metastasis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(5): 562-574.
[11]	XU Jianfei, LIN Li. Research progress in pharmacological and non-pharmacological treatments of hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 433-441.
[12]	LIU Guijian, CHENG Kuan, ZHU Wenqing, GE Junbo. Progress of hypertension pharmacological treatment [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 446-449.
[13]	MENG Shi, WANG Zhongqun. Research progress on human immunodeficiency virus-associated pulmonary arterial hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(12): 1431-1440.
[14]	ZHOU Shiqin, LUO Yali, ZHOU Wen, Qi Xiaofeng, XIAO Mengyong. Molecular mechanism and treatment of pulmonary fibrosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(10): 1133-1147.
[15]	DENG Yifan, HE Shenghu, WANG Daxin, DAI Chengye, XU Xiaoting, ZHANG Jing. Clinical study of effect of ezetimibe combined with statins on residual lipoprotein cholesterol and MACE events in patients undergoing emergency intervention with acute coronary syndrome [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(9): 1048-1052.